Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD – The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase ...

Click here to read the article now. MPS IVA is an autosomal recessive disease caused by a mutation in the N-acetylgalactosamine-5-sulfate sulfatase (GALNS) gene resulting in progressive system ...

Imdusiran targets hepatocytes using Arbutus’ novel covalently conjugated N-Acetylgalactosamine (GalNAc) delivery technology enabling subcutaneous delivery. Clinical data generated thus far has shown ...

This manuscript reports on the crystal structures of two glycosaminoglycan (GAG) lyases from the PL35 family, along with in vitro enzyme activity assays and comprehensive structure-guided mutagenesis.